Fluconazole resistance in Candida albicans: A review of mechanisms

European Review for Medical and Pharmacological Sciences

Volumn 8, Issue 2, 2004, Pages 69-77

  Casalinuovo, I A ^a   Di Francesco, P ^a   Garaci, E ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antifungal resistance; Candida albicans; Ergosterol; Fluconazole

Indexed keywords

ABC TRANSPORTER; ANTIFUNGAL AGENT; ARGININE; ASPARTIC ACID; CYCLIC AMP; CYCLOSPORIN A; CYTOCHROME P450; ERGOSTEROL; FLUCONAZOLE; GLUTAMIC ACID; ISOLEUCINE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; LEUCINE; LINOLEOYL COENZYME A DESATURASE; LYSINE; MICONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; POSACONAZOLE; RAVUCONAZOLE; SQUALENE MONOOXYGENASE; STEROID DELTA ISOMERASE; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; VALINE; VORICONAZOLE;

ABDOMINAL PAIN; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BIOFILM; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDIASIS; CELL WALL; DIARRHEA; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FUNGAL CELL; GENE MUTATION; GENE OVEREXPRESSION; HEADACHE; HUMAN; IMMUNE DEFICIENCY; LIVER DISEASE; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; PROPHYLAXIS; PUBLIC HEALTH SERVICE; REVIEW;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; GENE EXPRESSION; HUMANS;

EID: 3242659003     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Grant SM, Clissold SP. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
2. Millon L, Manteaux A, Reboux G. et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994; 32: 1115-1118.
3. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
4. Perea S. Lopez-Ribot JL, Wickes BL, et al. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 1695-1703.
5. Case CP, MacGowan AP, Brown NM, Reeves DS, Whitehead P, Felmingham D. Prophylactic oral fluconazole and candida fungaemia. Lancet 1991; 337: 790.
6. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-846.
7. Rangel-Frausto MS. Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NE-MIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
8. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260.
9. Bodey GP. Antifungal agents. In: GP Bodey, ed. Candidiasis: Pathogenesis, Diagnosis and Treatment. Raven Press, Ltd, New York: 1993: 388-401.
10. Hitchcock CA. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem Soc Trans 1991; 19: 782-787.
11. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393-400.
12. Joseph-Horne T, Hollomon DW. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett 1997; 149: 141-149.
13. Edwards JE Jr, Bodey GP, Bowden RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997; 25: 43-59.
14. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003; 123 (5 Suppl): 500S-503S.
15. Lamb DC, Kelly DE, Schunck WH, et al. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 1997; 272: 5682-5688.
16. Perea S, López-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684.
17. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76-81.
18. Marichal P, Vanden Bossche H. Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41: 2229-2237.
19. Holmberg K, Stevens DA. Resistance to antifungal drugs: current status and clinical implications. Curr Opin Anti-Infective Invest Drugs 1999; 1: 306-317.
20. López-Ribot JL, McAtee RK, Lee NL, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932-2937.
21. White TC, Pfaller MA, Rinaldi RG, Smith J, Redding SW. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis 1997; 3: S102-S109.
22. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2000; 44: 2693-2700.
23. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-1713.
24. Nakayama H, Nakayama N, Arisawa M, Aoki Y. In vitro and in vivo effects of 14α-demethylase (ERG11) depletion in Candida glabrata. Antimicrob Agents Chemother 2001; 45: 3037-3045.
25. White TC. The presence of an R467K aminoacid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α-demethylase in Candida albicans. Antimicrob Agents Chemother 1997; 41: 1488-1494.
26. Franz R, Kelly SE, Lamb DC, Kelly DE, Ruhne M, Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065-3072.
27. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
28. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-253.
29. Kelly SL, Lamb DC, Kelly DE. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 1999; 180: 171-175.
30. Lamb DC, Kelly DE, White TC, Kelly SE. The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 2000; 44: 63-67.
31. Morschhäuser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-248.
32. Marichal P, Koymans L, Willemsens S. et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-2713.
33. Maebashi K, Kudoh M, Nishiyama, et al. Proliferation of intracellular structure corresponding to reduced affinity of fluconazole for cytochrome P-450 in two low-susceptibility strains of Candida albicans isolated from a Japanese AIDS patient. Microbiol Immunol 2003; 47: 117-124.
34. Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002; 46: 3532-3539.
35. Rogers PD, Barker KS. Evaluation of differential gene expression in fluconazole-susceptible and - resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob Agents Chemother 2002; 46: 3412-3417.
36. Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother 2003; 47: 1220-1227.
37. Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 1998; 42: 2584-2589.
38. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH. Vanden Bossche H. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother 2001; 45: 1660-1670.
39. Bammert GF, Fostel JM. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob Agents Chemother 2000; 44: 1255-1265.
40. Mukhopadhyay K, Kohli A, Prasad R. Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother 2002; 46: 3695-3705.
41. Dimster-Denk D, Rine J, Phillips J, et al. Comprehensive evaluation of isoprenoid biosynthesis regulation in Saccharomyces cerevisiae utilizing the Genome Reporter Matrix. J Lipid Res 1999; 40: 850-860.
42. Cowen LE, Nantel A, Whiteway MS. et al. Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci U S A 2002; 99: 9284-9289.
43. Watson PF, Rose ME, Ellis SW, England H, Kelly SL. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 1989; 164: 1170-1175.
44. Kelly SL, Lamb DC, Kelly DE, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 1997; 400: 80-82.
45. Jackson CJ, Lamb DC, Manning NJ, Kelly DE, Kelly SL. Mutations in Saccharomyces cerevisiae sterol C5-desaturase conferring resistance to the CYP51 inhibitor fluconazole. Biochem Biophys Res Commun 2003; 309: 999-1004.
46. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404-2412.
47. Prasad R, De Wergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-329.
48. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
49. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-416.
50. Franz R, Ruhnke M, Morschhäuser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999; 42: 453-458.
51. Wirsching S, Michel S, Morschhäuser J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856-865.
52. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-2305.
53. Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25: 908-910.
54. Smriti, Krishnamurthy S, Dixit BL, Gupta CM, Milewski S, Prasad R. ABC transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen Candida albicans are general phospholipid translocators. Yeast 2002; 19: 303-318.
55. Dogra S, Krishnamurthy S, Gupta V. et al. Asymmetric distribution of phosphatidylethanolamine in C. albicans: possible mediation by CDR1, a multidrug transporter belonging to ATP binding cassette (ABC) superfamily. Yeast 1999; 15: 111-121.
56. Kohli A, Smriti, Mukhopadhyay K, Rattan A, Prasad R. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother 2002; 46: 1046-1052.
57. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-5394.
58. Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80: 903-908.
59. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888.
60. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-4340.
61. Spagnoli GC, Ausiello C, Casalinuovo I, Antonelli G, Dianzani F, Cassone A. Candida albicans and a phosphorylated glucomannan-protein fraction of its cell wall induce production of immune interferon by human peripheral blood mononuclear cells. IRCS Med Sci 1985; 13: 1190-1191.
62. Torosantucci A, Gomez MJ, Bromuro C, Casalinuovo I, Cassone A. Biochemical and antigenic characterization of mannoprotein constituents released from yeast and mycelial forms of Candida albicans. J Med Vet Mycol 1991; 29: 361-372.
63. Angiolella L, Micocci MM, D'Alessio S, Girolamo A, Maras B, Cassone A. Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance. Antimicrob Agents Chemother 2002; 46: 1688-1694.
64. Hazen KC, Mandell G, Coleman E, Wu G. Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiol Lett 2000; 183: 89-94.
65. Pujol C, Reynes J, Renaud F, et al. The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proc Natl Acad Sci U S A 1993; 90: 9456-9459.
66. Lockhart SR, Daniels KJ, Zhao R, Wessels D, Soll DR. Cell biology of mating in Candida albicans. Eukaryot Cell 2003; 2: 49-61.
67. Perepnikhatka V, Fischer FJ, Niimi M, et al. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bacteriol 1999; 181: 4041-4049.
68. Pujol C, Messer SA, Pfaller M, Soll DR. Drug resistance is not directly affected by mating type locus zygosity in Candida albicans. Antimicrob Agents Chemother 2003; 47: 1207-1212.
69. Rustad TR, Stevens DA, Pfaller MA, White TC. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 2002; 148: 1061-1072.
70. De Backer MD, Van Duck P. Progress in functional genomics approaches to antifungal drug target discovery. Trends Microbiol 2003; 11: 470-478.
71. Jain P, Akula I, Edlind I. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to anti-fungal azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2003; 47: 3195-3201.
72. Cruz MC, Goldstein AL, Blankenship JR. et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 2002; 21: 546-559.
73. Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 2003; 47: 956-964.
74. Marchetti O, Moreillon P, Entenza JM, et al. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 2003; 47: 1565-1570.
75. Di Francesco P, Gaziano R, Casalinuovo IA, et al. Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immuno-suppressed by morphine treatments. Clin Exp Immunol 1994; 97: 347-352.
76. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228-2230.
77. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-279.
78. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-517.
79. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-1080.
80. Sanglard D. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 2002; 20: 462-469.
81. Cowen LE, Anderson JB, Kohn LM. Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 2002; 56: 139-165.
82. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73-85.
83. Loeffler J, Stevens DA. Antifungal drug resistance. Clin Infect Dis 2003; 36 (Suppl 1): S31-S41.